Lixte Biotechnology Holdings Inc (LIXT) Stock Analysis
Lixte Biotechnology Holdings Inc (LIXT) is a publicly traded company in the HEALTHCARE sector. It trades at $7.04, carries a market capitalization of $89.28M. This page summarizes the public market data, fundamentals, and frequently asked questions for LIXT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.
Sector: HEALTHCARE - BIOTECHNOLOGY
Exchange: NASDAQ
Key Metrics
- Price: $7.04
- Market Cap: $89.28M
- EPS: $-1.15
- 52-Week High: $7.37
- 52-Week Low: $0.64
Market Sentiment
Lixte Biotechnology Holdings Inc currently has a Bullish sentiment score of 0.23.
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc. is a clinical-stage biotechnology company based in East Setauket, New York, focused on developing innovative therapies for serious diseases utilizing its proprietary biomarker technology. With a strong emphasis on precision medicine, Lixte is advancing a diverse pipeline of novel compounds aimed at addressing critical unmet needs in oncology and neurodegenerative disorders. The company's unique approach to identifying and targeting specific enzymes positions...
GNG Research Analysis
GNG Research scores Lixte Biotechnology Holdings Inc (LIXT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for LIXT.
Frequently Asked Questions
Does LIXT pay dividends?
Lixte Biotechnology Holdings Inc (LIXT) does not currently pay a regular dividend.
What is LIXT's market cap?
Lixte Biotechnology Holdings Inc (LIXT) has a market capitalization of $89.28M with a current stock price of $7.04.